Skip to content

Dydrogesterone Vs Combined Oral Contraceptive Pills for Treatment of Functional Ovarian cysts

Dydrogesterone Vs Combined Oral Contraceptive Pills for Treatment of Functional Ovarian cysts

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/051811
Enrollment
90
Registered
2023-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N830- Follicular cyst of ovary

Interventions

Intervention1: Dydrogesterone: Dydrogesterone is a highly selective progestogen, and due to its unique structure, unlike progesterone and many other progestins, binds almost exclusively to the progest

Sponsors

Jnmc
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Female participants at reproductive age of (18-44) years Ovarian cyst of diameter 3-10cm in size, present on one side with a single locule and content should be clear BMI: participants with BMI (18.5-24.9) of normal range and overweight category (25- 29.9) included

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The recession of cysts in time duration of 3 months Change in the menstrual pattern (frequency, regularity, duration and volume) Timepoint: The recession of cysts in time duration of 3 months Change in the menstrual pattern (frequency, regularity, duration and volume)

Secondary

MeasureTime frame
Duration of treatment needed Side effects Nausea, Vomiting, Weight gain, Acne, Effect on liver function tests Serious complications like thromboembolism delayed menses after treatment, drug interactions Timepoint: 3 months

Countries

India

Contacts

Public ContactShaikh Muneeba

Jawaharlal Nehru Medical College, Sawangi Meghe, Wardha

neemasacharya@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 9, 2026